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Since the Ebola virus (EBOV) was discovered in 1976, the 
recent 2014−2016 Ebola virus disease (EVD) outbreak in 
West Africa was the largest with 28,600 cases and about 
11,300 deaths.
This epidemic started in Guinea and spread rapidly across 
the borders in Sierra Leone and Liberia (1).
After an incubation period of 2 to 21 days EBOV 
manifests clinically as a hemorrhagic fever that can lead 
to death by hypovolemic shock and multisystem failure 
generally within a month of infection. 
Human-to-human transmission of EBOV occurs by direct 
contact (through cutaneous or mucosal lesions) with blood, 
secretions, organs or other body fluids of infected persons, 
and by indirect contact with environments contaminated with 
such fluids.
Although the West African epidemic has been declared 
formally extinguished in the spring of 2016, it has become 
increasingly clear that thousands of survivors remain at 
risk of post-EDV sequelae termed post-Ebola virus disease 
syndrome (PEVDS).
This term collects a group of physical and psychological 
symptoms affecting EVD survivors that include ocular 
disease, arthritis, hearing loss, abdominal pain and 
neuropsychiatric disorders as well as EBOV persistence in 
immune-privileged organs (2,3).
Approximately 14−34% of survivors are at risk of having 
ocular complications during convalescence of which the most 
common is uveitis (4-6).
While acute inflammation causes pain, tearing and 
photophobia, chronic inflammation can lead to severe 
hypovision due to cataract or more rarely to other 
complications such as hypotonia and phthisis bulbi (7,8).
Although it is not entirely clear how EBOV has been able 
to persist in the eye’s privileged immune site, several studies 
suggest that the pathogenesis of ocular involvement results 
from the ability of EBOV to overcome the blood-retinal 
barrier and persist in retinal pigment epithelial cells.
Zeng and his team found EBOV-RNA in privileged 
immune sites such as vitreous cavities, brains and testes 
of rhesus macaques that survived the experimental Ebola 
infection. In contrast, in the monkeys that died during the 
acute phase, the virus was located mainly inside endothelial 
cells (9).
Smith and colleagues in their study published in in 
Translational Vision Science & Technology introduced live 
EBOV to retinal pigment epithelium (RPE) cells in vitro. 
They observed that these cells are susceptible to infection 
by releasing high viral titers while continued their native 
function of expressing molecules that limit the ability of the 
immune system to fight infection (10).
Before the recent EDV broke out in West Africa it 
was thought that pathogenesis of uveitis may be a delayed 
hypersensitivity reaction to RNA viral antigens (11). 
The recent case report published by Varkey et al. in the 
New England Journal of Medicine challenges this assumption.
They have described the discovery of EBOV RNA in the 
aqueous humor 100 days after the clearance of the virus from 
the blood and therefore this makes us believe that uveitis is a 
direct result of the lytic action virus (12).
Cataract are therefore the main cause of visual impairment 
in survivors but the ability of EBOV to persist in ocular fluids 
for an unknown duration causes that cataract surgery in these 
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patients may be a potential risk of virus dissemination.
The manuscript of Shantha et al., reported in the journal 
EBioMedicine, “Ebola Virus Persistence in Ocular Tissues and 
Fluids (EVICT) Study: Reverse Transcription-Polymerase Chain 
Reaction and Cataract Surgery Outcomes of Ebola Survivors in 
Sierra Leone” is a cross-sectional study reported the clinical 
ophthalmic phenotypes, prevalence of EBOV RT-PCR in 
ocular fluid of a cohort of Sierra Leonean EVD survivors 
anticipating ocular surgery or with active uveitis (13).
The authors screened 137 EDV survivors of which 32 
(23%) were excluded: 16 showed an immature cataract, 11 
retinal or nerve optic disease that precluding visual recovery 
while 5 had hypotony or phthisis bulbi. 
Fifty EDV survivors (36%) were enrolled into the 
EVICT study: 46 eyes (92%) showed significant cataract, 
2 eyes (4%) active uveitis, 1 eye (2%) subluxed lens and 1 (2%) 
blind painful eye due to chronic uveitis. 
The median age of survivors was 24 years and 35 (70%) 
patients were female.
The authors also described how the survivors’ eyes showed 
the typical characteristics of post-uveitic cataract such as 
white uveitic cataract, posterior subcapsular cataract or white 
cataract with the iris-lens synechiae.
Forty-six survivors (92%) showed ocular signs due to a 
previous uveitis like posterior synechiae, keratic precipitates, 
band keratopathy and chorioretinal scars.
Therapies used before study enrollment included 
oral prednisone, topical prednisolone acetate and oral 
sulfamethoxazole/trimethoprim 800 mg/160 mg.
All 50 survivors underwent a sampling procedure of 
ocular fluid: 49 (98%) had an anterior chamber paracentesis 
(100−200 µL) and 1 patient had a vitreous tap (500 µL); 
pre- and post-sampling procedures a conjunctival swab 
was obtained. However, the authors noted that ocular 
samples were obtained in full personal protective equipment 
following guidelines from the WHO and Emory Serious 
Communicable Diseases Unit (SCDU).
All samples of aqueous humor, vitreous, and conjunctive 
were negative for EBOV RNA by RT-PCR at a median of 
19 months after EVD diagnosis in Phase I of ocular fluid 
sampling and at a median of 34 months after EVD in Phase 2 
of ocular fluid sampling.
Therefore 46 patients with cataract were assessed as 
eligible for manual small incision cataract surgery (MSICS) 
and 34 (74%) underwent MSICS with IOL implantation. 
All patients did not have active eye inflammation at the 
time of surgery.
Twenty-four eyes (70%) had a very low preoperative AV 
and met the concept of blindness based on the International 
Classification of Disease-10 (ICD-10).
The authors described how cataract surgery in survivors 
was followed by a great improvement in visual acuity that 
from a preoperative hand motion level passed to 20/70 after a 
month and 20/30 after 3−4 months from surgery.
The EVICT study is the first to methodically evaluate 
the persistence of EBOV in ocular fluids of survivors with 
cataract or active uveitis.
Although was limited in size the authors have shown how 
cataract surgery can be safely performed and with great visual 
performance results in all survivors tested negative for EBOV 
in their ocular fluid.
Although 92% of survivors have had a history of uveitis, 
this study cannot determine whether the virus was present 
during acute ocular inflammation.
Currently although vision loss due to cataract is a 
significant cause of disability in these patients, the World 
Health Organization cautions against elective surgery until 
research uncovers more about the persistence of the virus in 
body fluids (14).
Given that today there are about 10,000 survivors at risk of 
complications of uveitis it is desirable to develop appropriate 
indications and optimal protocols for intraocular surgery in 
these unfortunate patients. In fact vision restoration, after 
cataract surgery, can impact the quality of life of survivors 
who have already suffered so much due to the acute phase of 
EVD. 
Moreover, the development of a more precise knowledge 
of ocular viral persistence and the establishment of 
appropriate guidelines for eye surgery will undoubtedly prove 
very useful for dealing with other infectious diseases including 
Dengue fever, West Nile, Zika, and yellow fever (15). 
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